


1 **Supplementary Figures**


2



3

4 **Supplementary Figure 1 | 2D membranes assembled from lipid-like peptoids. a,**
5 Structures of membrane-forming peptoids Pep-1 – Pep-4. **b,** AFM images of biomimetic
6 membranes assembled from Pep-1, Pep-2, Pep-3, and Pep-4. These membranes exhibit a
7 similar height of ~3.5 nm. **c,** TEM images of biomimetic membranes assembled from
8 Pep-1, Pep-2, Pep-3, and Pep-4; 2% phosphotungstic acid was used for negative staining.

9




10

11


12 **Supplementary Figure 2 | XRD data of Pep-4 membranes and pre-assembled Pep-4**
13 **powder.** XRD data show that pre-assembled Pep-4 lyophilized from its H₂O and CH₃CN
14 (1:1) solution is amorphous before they are crystallized into highly-ordered membrane
15 structures.

16




17
18
19
20
21
22
23
24
25
26
27
28
29
30

Supplementary Figure 3 | TEM and AFM characterizations of Pep-5 membranes. **a** and **b**, high resolution TEM images to show the well-aligned hydrophilic strips of Pep-5 membranes along x-direction. **c**, AFM image of one Pep-5 membrane with height ~ 4.0 nm, the x-direction was labeled for comparison.




31
32
33
34
35
36
37
38
39


Supplementary Figure 4 | The importance of inter-peptoid hydrophobic interactions in the assembly of biomimetic membranes. **a**, AFM image of biomimetic membranes assembled from Pep-3 with the presence of over 0.5M NaCl. **b - e**, TEM images of biomimetic membranes assembled from Pep-2 in the mixture of water and acetonitrile ($v/v = 1:1$) at pH 5.6 (**b**), pH 7.4 (**c**), pH 10.5, and in a mixture of PBS (1X, pH 7.4) buffer and acetonitrile ($v/v = 1:1$) (**d**).



40
 41 **Supplementary Figure 5 | The influence of -Cl positions in the assembly of**
 42 **biomimetic membranes.** **a**, An AFM image showing the biomimetic membranes
 43 assembled from Pep-6. **b**, An AFM image showing the nanoparticles assembled from
 44 Pep-7. **c**, Structures of Pep-6 with six N-[2-(3-chlorophenyl)ethyl]glycines (N_{3-Cl}pe) and
 45 Pep-7 with six N-[2-(2-chlorophenyl)ethyl]glycines (N_{2-Cl}pe). **d**, XRD data showing
 46 biomimetic membranes assembled from both Pep-2 (with six N_{4-Cl}pe) and Pep-6 (with six
 47 N_{3-Cl}pe) are highly-crystalline, while nanoparticles assembled from Pep-7 (with six N₂₋
 48 Clpe) are amorphous; The change of the -Cl locations in hydrophobic side chains caused
 49 different packings of hydrophobic domains, the formation of amorphous nanoparticles
 50 induced by Pep-2 is probably due to the weak hydrophobic interactions as a result of
 51 large steric hindrance caused by N_{2-Cl}pe side chains.
 52




53
54 **Supplementary Figure 6 | The ordering of hydrophobic domains is the key to**
55 **forming membrane structures.** **a**, Structure of Pep-8 which has only three hydrophobic
56 N_{4-Clpe} residues; TEM data show that three N_{4-Clpe} residues are not enough to stabilize
57 the membrane structure. **b**, Structure of Pep-9 which has six N_{4-Clpe} and three hydrophilic
58 Nce residues; TEM and AFM data show that Pep-9 self-assemble into membranes even
59 with three Nce residues as hydrophilic domain. **c**, Structure of Pep-10 which has six N₄₋
60 Clpe and three hydrophilic Nte residues; TEM and AFM data show that Pep-10 self-
61 assemble into membranes even with three Nte as the hydrophilic domain; biomimetic
62 membranes assembled from Pep-10 in the mixture of PBS (1X, pH 7.4) buffer and
63 acetonitrile (v/v = 1:1). **d**, Structure of Pep-11 which has six N_{4-Clpe}, three Nce and three
64 Nae residues; TEM and AFM data show that Pep-10 self-assemble into membranes when
65 hydrophilic domain has half Nce and half Nae residues; biomimetic membranes
66 assembled from Pep-11 in the mixture of PBS (1X, pH 7.4) buffer and acetonitrile (v/v =
67 1:1).




68
69
70
71
72
73
74
75
76
77
78

Supplementary Figure 7 | The significance of hydrophobic interactions in the membrane formation and the similarity of designed peptoids and lipids. a, Structure of Pep-12 [(Nhex)₂(N4-clpe)₆(Nce)₆] and the TEM and AFM data of its self-assembled membranes. **b**, Structure of Pep-13 [(Nhex)₆(Nce)₆] and the TEM data of its assemblies. **c**, Structure of Pep-14 [(Nhex)₁₂(Nce)₆] and the TEM and AFM data of its self-assembled membranes.



79
80
81
82
83
84
85
86


Supplementary Figure 8 | Peptoid membrane formation is through an anisotropic crystallization process. a and b, Pep-3 nanoparticles and nanoribbons formed about one day later. **c and d**, Pep-3 membranes formed about two days later. 2% phosphotungstic acid was used for negative staining.



87

88 **Supplementary Figure 9 | Molecular dynamics of a structural model for peptoid**
 89 **nanomembranes.** Top view of the solvent accessible surface area for the first solvation
 90 shell water molecules above the membrane averaged over the last 200 ns of the trajectory
 91 for the membrane structure formed in N=96 simulations of the lipid-like Pep-1 (carboxyl
 92 side-chains were in the protonated state, and hydrophilic domains formed strips along x-
 93 direction). The height difference is color coded from blue (0nm) to red (2nm) setting the
 94 zero to the first solvation shell around the hydrophobic core of the membrane. The white
 95 rectangle represents the super cell of the simulation.


96
97



98
99


100 **Supplementary Figure 10 | Peptoid membranes assembled from 1-Ntyr-Pep-2.** AFM
 101 (a) and TEM (b) characterizations; 2% phosphotungstic acid was used for negative
 102 staining.

103
104




105
106
107
108
109
110
111

Supplementary Figure 11 | Peptoid membranes assembled from 1-Npyr-Pep-2. AFM (a), TEM (b), and SEM (c) characterizations.




112
113
114
115
116
117

Supplementary Figure 12 | Peptoid membranes assembled from 1-Nhex-Pep-2. TEM characterization of peptoid membranes; 2% phosphotungstic acid was used for negative staining.




118
119
120
121
122
123
124

Supplementary Figure 13 | Peptoid membranes assembled from 1,8-(Nazo)₂-Pep-2.
AFM characterization of peptoid membranes.




125
126
127
128
129
130
131

Supplementary Figure 14 | Peptoid membranes assembled from 1,8-(Ntrp)₂-Pep-2.
TEM characterization of peptoid membranes.




132
133
134
135
136
137
138

Supplementary Figure 15 | Peptoid membranes assembled from 1,8-(Nse)₂-Pep-2.
AFM (a) and TEM (b) characterizations; 2% phosphotungstic acid was used for negative staining.




139
140
141
142
143
144
145

Supplementary Figure 16 | Peptoid membranes assembled from 1,8-(Ntyr)₂-Pep-2.
AFM (a) and TEM (b) characterizations; 2% phosphotungstic acid was used for negative staining.




146
147
148
149
150
151
152
153
154
155

Supplementary Figure 17 | Peptoid membranes assembled from 1-Nse-8-Ntyr-Pep-2. AFM (a) and TEM (b) characterizations; 2% phosphotungstic acid was used for negative staining.




156
157
158
159
160
161
162
163

Supplementary Figure 18 | Peptoid membranes assembled from 13-Nte-Pep-2. AFM (a) and TEM (b) characterizations; 2% phosphotungstic acid was used for negative staining.




164
165
166
167
168
169
170
171
172

Supplementary Figure 19 | Peptoid membranes assembled from 13-Nhis-Pep-2.
AFM (a) and TEM (b) characterizations; 2% phosphotungstic acid was used for negative staining.




173
174
175
176
177
178
179
180

Supplementary Figure 20 | Peptoid membranes assembled from 13-Ntyr-Pep-2.
AFM (a) and TEM (b) characterizations; 2% phosphotungstic acid was used for negative staining.




181
182
183
184
185
186
187
188
189
190

Supplementary Figure 21 | Peptoid membranes assembled from 13-Nbce-Pep-2.
AFM characterization of peptoid membranes.




191
192
193
194
195
196
197

Supplementary Figure 22 | Peptoid membranes assembled from 1,14-(Nse)₂-Pep-2.
AFM (a) and TEM (b) characterizations; 2% phosphotungstic acid was used for negative staining.




198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217

Supplementary Figure 23 | Peptoids with functional objects assembled into biomimetic membranes with similar structures. XRD data of membranes assembled from 1-Ntyr-Pep-2, 1,8-(Nse)₂-Pep-2, 13-Nhis-Pep-2, 1,14-(Nse)₂-Pep-2, and 1,8-(Nazo)₂-Pep-2; they all exhibit similar XRD patterns to those of Pep-2, showing structural similarity.



218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245


Supplementary Figure 24 | Incorporating functional objects through co-crystallization. **a**, A SEM image showing 2D membranes co-assembled from **Pep-2** and **Ncd-Pep-2** with molar ratio 4:1. **b**, An AFM image showing the co-assembled membranes. **c**, UPLC data showing the co-assembled membranes from **Ncd-Pep-2** & **Pep-2** have the molar ratio of **Ncd-Pep-2** vs **Pep-2** is almost 1 : 4 (integration of UPLC peaks). **d**, A TEM image showing 2D membranes co-assembled from **Pep-2** and **Ncd-Pep-2** with molar ratio 9:1. **e**, A TEM image showing 2D membranes co-assembled from **Pep-2** and **Ncd-Pep-2** with molar ratio 1:1. **f**, A SEM image showing 2D membranes co-assembled from **Pep-2** and **Ncd-Pep-2** with molar ratio 1:1.



246
247
248
249
250
251
252
253
254
255
256
257
258


Supplementary Figure 25 | Peptoid membranes are highly stable. **a**, An *in situ* AFM image of one Pep-3 membrane in pure water, some defects were purposely introduced using mechanical forces for membrane self-repair experiments. **b**, An *in situ* AFM images show that no significant disruptions were observed when peptoid membranes were incubated in H₂O&CH₃CN (1:1) solution for over 2h. **c**, An *in situ* AFM image show the peptoid membrane is stable even in pure CH₃CN for over 2h. **d**, A SEM image of **Pep-2** membranes which were incubated in pure CH₃CN for over 6h. **e**, A SEM image showing peptoid membranes co-assembled from **Pep-2** and Ncd-**Pep-2** with molar ratio 1:1, these membranes were incubated in pure CH₃CN for over 6h before SEM experiment. **f**, A SEM image showing the 1-Npyr-**Pep-2** membranes after they were incubated in pure CH₃CN for over 6h.

259
260



261
262
263
264
265
266
267

Supplementary Figure 26 | Salt-induced thickness changes of peptoid membranes. **a**, *In situ* AFM image of one Pep-3 membrane in pure water, 10 mM NaCl, 100 mM NaCl, 1.0M NaCl and 1.5 M NaCl showing membrane thickness change. **b**, *In situ* AFM image of one Pep-3 membrane in pure water, 0.1x PBS, 1x PBS and 10x PBS buffer showing membrane thickness change.




268

269 **Supplementary Figure 27 | The nanoscale patterning of Ncd-Pep-2 within Pep-2**
 270 **membranes. a,** An *In situ* AFM image showing one Pep-2 membrane in water. **b,** An *In*
 271 *situ* AFM image showing one Pep-2 membrane with mechanically-induced defects. **c,** An
 272 *In situ* AFM image showing the nanoscale patterning of Ncd-Pep-2 within Pep-2
 273 membrane.

274


275




276

277 **Supplementary Figure 28 | The nanoscale patterning of NHS-Rhodamine-labeled**
 278 **Pep-3 within Pep-3 membranes. a,** Structure of NHS-Rhodamine-labeled Pep-3. **b,** The
 279 nanoscale patterning of NHS-Rhodamine-Pep-3 within Pep-3 membranes; (left) An *In*
 280 *situ* AFM image showing one Pep-2 membrane in water; (middle) An *In situ* AFM image
 281 showing one Pep-3 membrane with mechanically-induced defects; (right) An *In situ*
 282 AFM image showing the nanoscale patterning of NHS-Rhodamine-Pep-3 within Pep-3
 283 membrane.

284
285
286
287
288
289




290
291




292
293
294
295
296
297
298
299
300
301
302
303

Supplementary Figure 29 | UPLC-MS characterization of Pep-1. (Top image) UPLC characterization of Pep-1 with the gradient of 40 - 80% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-1.

304
305
306




307
308




309
310
311
312
313
314
315
316
317
318

Supplementary Figure 30 | UPLC-MS characterization of Pep-2. (Top image) UPLC characterization of Pep-2 with the gradient of 55 - 75% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-2.

319
320
321




322
323




324
325
326
327
328
329
330
331
332

Supplementary Figure 31 | UPLC-MS characterization of Pep-3. (Top image) UPLC characterization of Pep-3 with the gradient of 55 - 75% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-3.

333
334
335
336
337
338
339




340
341
342




343
344
345
346
347
348
349
350
351
352
353
354
355
356

Supplementary Figure 32 | UPLC-MS characterization of Pep-4. (Top image) UPLC characterization of Pep-4 with the gradient of 5 - 95% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-4.

357
358
359
360
361
362




363
364
365




366
367
368
369
370
371
372
373
374

Supplementary Figure 33 | UPLC-MS characterization of Pep-5. (Top image) UPLC characterization of Pep-5 with the gradient of 40 - 80% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-5.

392
393
394



395
396
397




398
399


400 **Supplementary Figure 35 | UPLC-MS characterization of Pep-7.** (Top image) UPLC
401 characterization of Pep-7 with the gradient of 40 - 80% CH₃CN in H₂O. (Bottom image)
402 MS characterization of Pep-7.

403
404
405
406
407
408
409

410
411
412
413




414
415
416
417




418
419
420
421
422
423
424
425
426
427

Supplementary Figure 36 | UPLC-MS characterization of Pep-8. (Top image) UPLC characterization of Pep-8 with the gradient of 5 - 95% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-8.

428
429
430
431
432




433
434
435




436
437
438
439
440
441
442
443

Supplementary Figure 37 | UPLC-MS characterization of Pep-9. (Top image) UPLC characterization of Pep-9 with the gradient of 60 - 65% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-9.

456



457
458




459
460
461
462
463
464

Supplementary Figure 39 | UPLC-MS characterization of Pep-11. (Top image) UPLC characterization of Pep-11 with the gradient of 45 - 65% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-11.


465

466

467




468
469




470
471

472 **Supplementary Figure 40 | UPLC-MS characterization of Pep-12.** (Top image) UPLC
473 characterization of Pep-12 with the gradient of 5 - 95% CH₃CN in H₂O. (Bottom image)
474 MS characterization of Pep-12.
475

476



477
478



479
480


481 **Supplementary Figure 41 | UPLC-MS characterization of Pep-13.** (Top image) UPLC
482 characterization of Pep-13 with the gradient of 5 - 95% CH₃CN in H₂O. (Bottom image)
483 MS characterization of Pep-13.

484
485

486


487

488



489

490



491

492

Supplementary Figure 42 | UPLC-MS characterization of Pep-14. (Top image) UPLC characterization of Pep-14 with the gradient of 80 - 100% CH₃CN in H₂O. (Bottom image) MS characterization of Pep-14.

496

497

498

499

500

501

502


503

504


505

506

507
508




509
510




511
512
513
514
515
516
517
518
519
520
521
522

Supplementary Figure 43 | UPLC-MS characterization of 1-Ntyr-Pep-2. (Top image) UPLC characterization of 1-Ntyr-Pep-2 with the gradient of 55 - 75% CH₃CN in H₂O. (Bottom image) MS characterization of 1-Ntyr-Pep-2.

523
524
525
526
527



528
529
530




531
532


Supplementary Figure 44 | UPLC-MS characterization of 1-Npyr-Pep-2. (Top image) UPLC characterization of 1-Npyr-Pep-2 with the gradient of 65 - 70% CH₃CN in H₂O. (Bottom image) MS characterization of 1-Npyr-Pep-2.

536
537
538
539
540
541
542
543
544
545
546
547

548
549



550
551




552
553

554 **Supplementary Figure 45 | UPLC-MS characterization of 1-Nhex-Pep-2.** (Top
555 image) UPLC characterization of 1-Nhex-Pep-2 with the gradient of 5 - 95% CH₃CN in
556 H₂O. (Bottom image) MS characterization of 1-Nhex-Pep-2.


557
558
559
560
561
562
563

564

565




566
567




568
569

570 **Supplementary Figure 46 | UPLC-MS characterization of 1,8-(Nazo)₂-Pep-2.** (Top
571 image) UPLC characterization of 1,8-(Nazo)₂-**Pep-2** with the gradient of 5 - 95% CH₃CN
572 in H₂O. (Bottom image) MS characterization of 1,8-(Nazo)₂-**Pep-2**.
573

574




575
576




577
578

579 **Supplementary Figure 47 | UPLC-MS characterization of 1,8-(Ntrp)₂-Pep-2.** (Top
580 image) UPLC characterization of 1,8-(Ntrp)₂-Pep-2 with the gradient of 5 - 95% CH₃CN
581 in H₂O. (Bottom image) MS characterization of 1,8-(Ntrp)₂-Pep-2.
582

583



584
585




586
587
588
589
590
591


Supplementary Figure 48 | UPLC-MS characterization of 1,8-(Nse)₂-Pep-2. (Top image) UPLC characterization of 1,8-(Nse)₂-Pep-2 with the gradient of 55 - 75% CH₃CN in H₂O. (Bottom image) MS characterization of 1,8-(Nse)₂-Pep-2.

592

593



594
595



596
597


598 **Supplementary Figure 49 | UPLC-MS characterization of 1,8-(Ntyr)₂-Pep-2.** (Top
599 image) UPLC characterization of 1,8-(Ntyr)₂-Pep-2 with the gradient of 55 - 75%
600 CH₃CN in H₂O. (Bottom image) MS characterization of 1,8-(Ntyr)₂-Pep-2.

601

602


603

604



605

606



607

608

609

610


611

612

Supplementary Figure 50 | UPLC-MS characterization of 1-Nse-8-Ntyr-Pep-2. (Top image) UPLC characterization of 1-Nse-8-Ntyr-Pep-2 with the gradient of 5 - 95% CH₃CN in H₂O. (Bottom image) MS characterization of 1-Nse-8-Ntyr-Pep-2.


613

614



615

616



617

618

619 **Supplementary Figure 51 | UPLC-MS characterization of 13-Nte-Pep-2.** (Top image)

620 UPLC characterization of 13-Nte-Pep-2 with the gradient of 5 - 95% CH₃CN in H₂O.


621 (Bottom image) MS characterization of 13-Nte-Pep-2.

622


623

624

625



626
627




628
629

630 **Supplementary Figure 52 | UPLC-MS characterization of 13-Nhis-Pep-2.** (Top
631 image) UPLC characterization of 13-Nhis-Pep-2 with the gradient of 50 - 70% CH₃CN in
632 H₂O. (Bottom image) MS characterization of 13-Nhis-Pep-2.


633
634

635

636



637
638



639
640

641

642


643

644


Supplementary Figure 53 | UPLC-MS characterization of 13-Ntyr-Pep-2. (Top image) UPLC characterization of 13-Ntyr-Pep-2 with the gradient of 5 - 95% CH₃CN in H₂O. (Bottom image) MS characterization of 13-Ntyr-Pep-2.

645

646



647
648




649
650

651 **Supplementary Figure 54 | UPLC-MS characterization of 13-Nbce-Pep-2.** (Top
652 image) UPLC characterization of 13-Nbce-Pep-2 with the gradient of 55 - 70% CH₃CN
653 in H₂O. (Bottom image) MS characterization of 13-Nbce-Pep-2.


654

655

656



657
658



659

660

661

662

663

664

665


666

667


668

Supplementary Figure 55 | UPLC-MS characterization of 1,14-(Nse)₂-Pep-2. (Top image) UPLC characterization of 1,14-(Nse)₂-Pep-2 with the gradient of 55 - 75% CH₃CN in H₂O. (Bottom image) MS characterization of 1,14-(Nse)₂-Pep-2.

669
670
671
672



673
674



675
676


677 **Supplementary Figure 56 | UPLC-MS characterization of Ncd-Pep-2.** (Top image)
678 UPLC characterization of Ncd-Pep-2 with the gradient of 50 - 70% CH₃CN in H₂O.
679 (Bottom image) MS characterization of Ncd-Pep-2.

680
681
682
683

684


685

686



687

688



689

690

691 **Supplementary Figure 57 | UPLC-MS characterization of NHS-Rhodamine-labeled**
692 **Pep-3.** (Top image) UPLC characterization of NHS-Rhodamine-labeled Pep-3 with the
693 gradient of 5 - 95% CH₃CN in H₂O. (Bottom image) MS characterization of NHS-
694 Rhodamine-labeled Pep-3.


695 Supplementary Methods

696 **Materials**

697 β -alanine tert-butyl ester hydrochloride was purchased from Chem-Impex International,
698 Inc. was deprotected by the sodium hydroxide aqueous solution, then extracted with
699 CH_2Cl_2 , filtered and rotary evaporated for further reaction. *N,N'*-
700 diisopropylcarbodiimide, bromoacetic acid and trifluoroacetic acid (TFA) were purchased
701 from Chem-Impex International, Inc. 2-(4-Chlorophenyl)ethylamine, cysteamine
702 hydrochloride and 4-aminoazobenzene were purchased from VWR. 1-
703 Pyrenemethylamine hydrochloride, chloroacetic acid, histamine, ammonium hydroxide
704 solution (28.0-30.0% NH_3 basis), tyramine, tryptamine and β -cyclodextrin were
705 purchased from Sigma-Aldrich. 4'-Aminobenzo-15-crown 5-Ether were purchased from
706 TCI America. *p*-Toluenesulfonyl chloride and triphenylmethanol were purchased from
707 Fisher Scientific. 2-(Tritylthio)ethanamine was synthesized according to the reported
708 literature.¹ 2-(2-(2-methoxyethoxy)ethoxy)ethylamine was synthesized with the same
709 protocol reported in the literature.² All other amine submonomers and other reagents are
710 obtained from commercial sources and used without further purification.

711

712 **Synthesis of 2-(tritylthio)ethanamine**




713

714 2-(tritylthio)ethanamine was synthesized according to the reported literature.¹ For the
715 detail synthesis route, cysteamine hydrochloride (1.931 g, 17 mmol) was dissolved in the
716 8 mL of TFA. Triphenylmethanol (4.426 g, 17 mmol) were added, reacting for 40
717 minutes at room temperature. TFA was evaporated under a stream of nitrogen gas, and
718 the resulted residue was triturated with ethyl ether. The white precipitate was filtered and
719 then partitioned with aqueous NaOH (25 mL, 1M). Finally, the crude product solution
720 was extracted with ethyl acetate. The organic layer was dried with anhydrous Na_2SO_4 .
721 The white solid product were obtained after the rotary evaporation and dried in a vacuum
722 drying oven at 40 °C for 24 hours (4.408 g, 13.8 mmol, Yield: 81%; MS *m/z*: (positive
723 ion ESI) 639.15 for $[2\text{M}]^+$.

724

725 **Synthesis of mono-6-amino-6-deoxy-cyclodextrin (CD-NH₂)**



726

727 In the first step, mono-6-(*p*-toluenesulfonyl)-6-deoxy-cyclodextrin (CD-Ts) was
 728 synthesized according to the reported literature.³ β -Cyclodextrin (50 g, 44.1 mmol) was
 729 dissolved in the 300 mL of deionized water, immersed in the 0 °C ice bath. NaOH (5.475 g,
 730 137 mmol) was added, leading to the complete dissolution of β -cyclodextrin. *p*-
 731 Toluenesulfonyl chloride (8.4 g, 44.1 mmol) dissolved in 30 mL of acetonitrile was step-
 732 wisedly dropped into the solution. After that, the mixture was reacting 3 hours at room
 733 temperature. pH value of the mixture was adjusted to about 9.0, putting in the 4 °C fridge
 734 overnight. The crude product was filtered and dried in a vacuum drying oven at 50 °C for
 735 2 days. The product of CD-Ts was obtained as white solid (10.977 g, 8.5 mmol, Yield:
 736 19.3%).

737 CD-Ts (4.723 g, 3.66 mmol) was added into the single-neck round-bottom flask. 50 mL
 738 of ammonium hydroxide solution was added to complete dissolve the sample, reacting
 739 for 3 days at room temperature. The crude product was precipitated in the ice cold
 740 acetone for 3 times and dried in a vacuum drying oven at 30 °C for 24 hours. The final
 741 product of CD-NH₂ was white solid (4.040g, 3.56 mmol, Yield: 97%), MS *m/z*: (positive
 742 ion ESI) 1134.29 for [M⁺].
 743

744 Peptoid synthesis

745 Methods for the automated solid-phase synthesis

746 Lipid-like peptoids were synthesized on a commercial Aapptec Apex 396 robotic
 747 synthesizer using a modified solid-phase submonomer synthesis method as described
 748 previously.^{4,5} Rink amide resin (0.09 mmol) was used to generate C-terminal amide
 749 peptoids. In this method, the Fmoc group on the resin was deprotected by adding 2 mL
 750 of 20% (v/v) 4-Methylpiperidine/*N,N*-dimethylformamide (DMF), agitating for 20 min,
 751 draining, and washing with DMF. All DMF washes consisted of the addition of 1.5 mL of
 752 DMF, followed by agitation for 1 min (repeated five times). An acylation reaction was
 753 then performed on the amino resin by the addition of 1.6 mL of 0.6 M bromoacetic acid
 754 in DMF, followed by 0.35 mL of 50% (v/v) *N,N*-diisopropylcarbodiimide (DIC)/DMF.
 755 The mixture was agitated for 30 minutes at room temperature, drained, and washed with
 756 DMF for 5 times. Nucleophilic displacement of the bromide with various primary amines
 757 occurred by a 1.6 mL addition of the primary amine monomer as a 0.6 M solution in *N*-
 758 methyl-2-pyrrolidone (NMP), followed by agitation for 60 minutes at room temperature.
 759 The monomer solution was drained from the resin, and the resin was washed with DMF
 760 for 5 times. The acylation and displacement steps were repeated until a lipid-like peptoid
 761 of the desired length was synthesized.
 762

763 Methods for the manual synthesis

764 Rink amide resin (0.09 mmol) was used to generate C-terminal amide peptoids. In the
765 synthesis procedure, the Fmoc groups on the resin were deprotected by adding 2 mL of
766 20% (v/v) 4-methylpiperidine/*N,N*-dimethylformamide (DMF), agitating for 40 min,
767 filtering, and washing with DMF. For all DMF washes, 1 mL DMF was added and then
768 agitated for 1 min (repeated five times). An acylation reaction was then performed on the
769 amino resin by the addition of 1.5 mL of 0.6 M bromoacetic acid in DMF, followed by
770 adding 0.30 mL of 50% (v/v) *N,N*-diisopropylcarbodiimide (DIC)/DMF. The mixture
771 was agitated for 10 minutes at room temperature, filtered and washed with DMF for 5
772 times. Nucleophilic displacement of the bromine with different primary amines occurred
773 by the addition of 1.5 mL of 0.6 M primary amine monomer in *N*-methyl-2-pyrrolidone
774 (NMP), followed by the agitation for 10 minutes at room temperature. The monomer
775 solution were filtered from the resin, and washed with DMF for 5 times. The acylation
776 and displacement steps were repeated until the designed peptoid was synthesized.

777

778 **Methods for synthesizing other uncommon sequences**

779 **Synthesis of Pep-3:** The resulting rink amide resins (0.09 mmol) containing Pep-2
780 obtained from automated solid-phase synthesis were mixed with a DMF solution of
781 Fmoc-6-aminohexanoic acid (1.5 mL, 0.9 mmol) and 0.50 mL of 50% (v/v) *N,N*-
782 diisopropylcarbodiimide (DIC)/DMF. The mixture was agitated overnight at room
783 temperature, filtered, and washed well with DMF. The terminal Fmoc group was
784 deprotected by adding 2 mL of 20% (v/v) 4-methylpiperidine/DMF. The mixture was
785 agitated for 40 min, filtered, and washed well with DMF.

786

787 **Synthesis of Ncd-Pep-2:** The resulting rink amide resins (0.09 mmol) containing Pep-2
788 obtained from automated solid-phase synthesis were mixed with a DMF solution of
789 bromoacetic acid (1.5 mL, 0.9 mmol) and 0.30 mL of 50% (v/v) *N,N*-
790 diisopropylcarbodiimide (DIC)/DMF. The mixture was agitated for 10 minutes at room
791 temperature, filtered and washed with DMF for 5 times. In the nucleophilic displacement
792 step, 1.5 mL of 0.3 M CD-NH₂ in DMF and K₂CO₃ (100 mg, 0.72 mmol) were added,
793 followed by the agitation for 3 days at 40 °C. The monomer solution were filtered from
794 the resin, washed with deionized water for 5 times, and then washed well with DMF.

795

796 **Synthesis of peptoids containing *N*-[4-(2-phenyldiazenyl)phenyl]glycines (Nazo)**
797 **13-Nazo-Pep-2:** Rink amide resins (0.09 mmol) containing Pep-2 were mixed with 1.5
798 mL of 0.6 M bromoacetic acid in DMF, followed by adding 0.30 mL of 50% (v/v) *N,N*-
799 diisopropylcarbodiimide (DIC)/DMF. The mixture was agitated for 10 minutes at room
800 temperature, filtered and washed with DMF. In the nucleophilic displacement step, a
801 NMP solution of 4-Aminoazobenzene (1.5 mL, 0.9 mmol) and tetrabutylammonium
802 iodide (TBAI, 100 mg, 0.27mmol) was added into the above resins, followed by the
803 agitation for 2 days at 40 °C. The resulting resins were first washed with deionized water
804 for 5 times and then washed with DMF for 5 times.

805

806 **Synthesis of peptoids containing *N*-[benzo-15-crown-5-ether]glycines (Nbce)**
807 **13-Nbce-Pep-2:** Similar to the synthesis of **13-Nazo-Pep-2**, in the nucleophilic
808 displacement step, a NMP solution 4'-Aminobenzo-15-crown 5-Ether (1.5 mL, 0.9 mmol)
809 and tetrabutylammonium iodide (TBAI, 100 mg, 0.27mmol) were used, followed by the

810 agitation for 2 days at 40 °C. The resulting resins were first washed with deionized water
811 for 5 times and then washed with DMF for 5 times.

812

813 **Synthesis of peptoids containing [2-(4-imidazolyl)ethylamine]glycines (Nhis)**

814 **13-Nhis-Pep-2:** Rink amide resins (0.09 mmol) containing Pep-2 were mixed with 1.5
815 mL of 0.6 M chloroacetic acid in DMF, followed by adding 0.30 mL of 50% (v/v) N,N-
816 diisopropylcarbodiimide (DIC)/DMF. The mixture was agitated for 10 minutes at room
817 temperature, filtered and washed with DMF. In the nucleophilic displacement step, a
818 NMP solution of histamine (1.5 mL, 0.9 mmol) was added into the above resins, followed
819 by the agitation for one hour at 40 °C. The resulting resins were washed well with DM.

820

821 *Notes: After introducing Nhis in the peptoid, chloroacetic acid was used instead of*
822 *bromoacetic acid for all subsequent steps of acylation in order to reduce side product*
823 *formation as described previously.⁶ In the displacement step, primary amines substituted*
824 *the chloride atom under the condition of agitation 1 hour at 40 °C.*

825

826 **Synthesis of peptoids containing N-[2-(1H-indol-3-yl)ethyl]glycine (Ntrp)**

827 **13-Ntrp-Pep-2:** Rink amide resins (0.09 mmol) containing Pep-2 were mixed with 1.5
828 mL of 0.6 M chloroacetic acid in DMF, followed by adding 0.30 mL of 50% (v/v) N,N-
829 diisopropylcarbodiimide (DIC)/DMF. The mixture was agitated for 10 minutes at room
830 temperature, filtered and washed well with DMF. In the nucleophilic displacement step, a
831 NMP solution of tryptamine (1.5 mL, 0.9 mmol) was added into the above resins,
832 followed by the agitation for one hour at 40 °C. The resulting resins were washed with
833 DMF for 5 times.

834

835 *Notes: After introducing Ntrp in the peptoid, chloroacetic acid was used instead of*
836 *bromoacetic acid for all subsequent steps of acylation in order to reduce side product*
837 *formation as described previously.⁶ In the displacement step, primary amines substituted*
838 *the chloride atom under the condition of agitation 1 hour at 40 °C.*

839

840 **Synthesis of peptoids containing N-[(1-pyrenemethyl)]glycines (Npyr)**

841 **1-Npyr-Pep-2:** Rink amide resins (0.09 mmol) containing Pep-2 were mixed with 1.5
842 mL of 0.6 M bromoacetic acid in DMF, followed by adding 0.30 mL of 50% (v/v) N,N-
843 diisopropylcarbodiimide (DIC)/DMF. The mixture was agitated for 10 minutes at room
844 temperature, filtered and washed with DMF for 5 times. In the nucleophilic displacement
845 step, a 3.0 mL methanol solution of 1-Pyrenemethylaminehydrochloride (0.9 mmol) and
846 N,N-Diisopropylethylamine (DIPEA) (0.9 mmol) was added into the above resins,
847 followed by the agitation for 30 minutes at room temperature. The resulting resins were
848 washed with DMF for 5 times.

849

850 **Synthesis of NHS-Rhodamine-labeled Pep-3:**

851 After the synthesis of **Pep-3**, 2 mL of DMF solution of NHS-Rhodamine (0.9 mmol) and
852 0.50 mL of 50% (v/v) N,N-diisopropylcarbodiimide (DIC)/DMF were added and mixed
853 with resins containing **Pep-3**, followed by the agitation for overnight at room
854 temperature. The monomer solution were filtered from the resin, and washed with DMF
855 for 5 times.

856 **Peptoid cleavage and HPLC purification**

857

858 For most of lipid-like peptoids, their final crude products were obtained by cleaving the
859 corresponding resins with addition of 95% trifluoroacetic acid (TFA) in water. For
860 peptoids containing *N*-(2-thiolethyl)glycine (Nse) side chains, their crude products were
861 cleaved from the corresponding resins with the addition of a solution containing 90%
862 TFA, 5% triisopropylsilane and 5% water. TFA was then evaporated under a stream of
863 N₂ gas. Finally, crude peptoids were dissolved in H₂O/CH₃CN (v/v=1:1) for HPLC
864 purification.

865

866 All peptoids were purified by reverse-phase HPLC on a XBridge™ Prep C18 OBD™
867 column (10 μm, 19 mm × 100 mm), using a narrow gradient of acetonitrile in H₂O with
868 0.1% TFA over 15 min. Purified peptoids were analyzed using Waters ACQUITY
869 reverse-phase UPLC (the corresponding gradient at 0.4 mL/min over 7 min at 40°C with
870 a ACQUITY®BEH C18, 1.7 μm, 2.1 mm × 50 mm column) that was connected with a
871 Waters SQD2 mass spectrometry system (See Supplementary Figs 29 – 57). The final
872 peptoid product was lyophilized from its solution in a mixture (v/v = 1:1) of water and
873 acetonitrile. The peptoid powder was finally divided into small portions (1.0 or 2.0 × 10⁻⁶
874 mol) and stored at -80°C.

875


876 **Peptoid sequences and their UPLC-MS characterizations** (See Supplementary Figs 29
877 – 57).

878 Structures of the synthesized peptoids and molecular weight of each peptoid as
879 determined by mass spectrometry are shown below.

880

881 Pep-1: 1965.6 (Molecular weight), 1966.4 (Found:[M+H]⁺), 983.7 (Found:[M/2+H]⁺).

882 UPLC-MS spectra were shown in Supplementary Fig. 29.




883

884

885 Pep-2: 1965.6 (Molecular weight), 983.6 (Found:[M/2+H]⁺), 1966.3 (Found:[M+H]⁺).


886 UPLC-MS spectra were shown in Supplementary Fig. 30.



887


888

889 Pep-3: 2078.8 (Molecular weight), 2079.4 (Found:[M+H]⁺), 1040.4 (Found: [M/2+H]⁺).
890 UPLC-MS spectra were shown in Supplementary Fig. 31.
891




892
893
894

895 Pep-4: 2060.7 (Molecular weight), 2061.71 (Found:[M+H]⁺), 1031.38
896 (Found:[M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 32.




897
898
899

900 Pep-5: 2199.93 (Molecular weight), 2200.41 (Found:[M+H]⁺), 1100.4 (Found:
901 [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 33.




902
903

904 Pep-6: 1965.6 (Molecular weight), 1966.3 (Found:[M+H]⁺), 983.4 (Found: [M/2+H]⁺).
905 UPLC-MS spectra were shown in Supplementary Fig. 34.
906




907

908 Pep-7: 1965.6 (Molecular weight), 1966.4 (Found:[M+H]⁺), 983.6 (Found: [M/2+H]⁺).
909 UPLC-MS spectra were shown in Supplementary Fig. 35.
910




911
912

913 Pep-8 [(N₄-Clpe)₃Nce₆]: 1378.7 (Molecular weight), 1379.5 (Found:[M+H]⁺). UPLC-MS
914 spectra were shown in Supplementary Fig. 36.




915
916

917 Pep-9 [(N₄-Clpe)₆Nce₃]: 1578.3 (Molecular weight), 1579.6 (Found:[M+H]⁺). UPLC-MS
918 spectra were shown in Supplementary Fig. 37.




919
920

921 Pep-10 [(N₄-Clpe)₆Nte₃, Nte = N-2-(2-(2-methoxyethoxy)ethoxy)ethylglycine]: 1800.6
922 (Molecular weight), 1801.6 (Found:[M+H]⁺), 901.8 (Found:[M/2+H]⁺). UPLC-MS
923 spectra were shown in Supplementary Fig. 38.
924



925


926 Pep-11 [(N_{4-Cl}pe)₆(NceNae)₃]: 1878.6 (Molecular weight), 1881.4 (Found:[M+H]⁺),
927 940.1 (Found: [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 39.



928
929
930

931 Pep-12 [(Nhex)₂(N4-clpe)₆(Nce)₆]: 2248.0 (Molecular weight), 2248.7 (Found:[M+H]⁺),
932 1124.8 (Found: [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 40.


933



934
935
936

937 Pep-13 [(Nhex)₆(Nce)₆]: 1639.0 (Molecular weight), 1640.0 (Found:[M+H]⁺). UPLC-MS
938 spectra were shown in Supplementary Fig. 41.


939



940
941


942 Pep-14 [(Nhex)₁₂(Nce)₆]: 2486.3 (Molecular weight), 2486.5 (Found:[M]⁺), 1243.8
943 (Found: [M/2]⁺). UPLC-MS spectra were shown in Supplementary Fig. 42.

944




945
946
947
948

949 1-Ntyr-Pep-2: 2142.8 (Molecular weight), 2143.4 (Found:[M+H]⁺), 1072.3
950 (Found:[M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 43.




951
952

953 1-Npyr-Pep-2: 2236.92 (Molecular weight), 2237.70 (Found: [M+H]⁺), 1119.59
954 (Found:[M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 44.




955
956

957 1-Nhex-Pep-2: 2106.81 (Molecular weight), 2108.15 (Found:[M+H]⁺), 1054.25
958 (Found:[M/2]⁺). UPLC-MS spectra were shown in Supplementary Fig. 45.




959
960

961 1,8-(Nazo)₂-Pep-2: 2240.12 (Molecular weight), 2440.22 (Found:[M]⁺), 1221.0 (Found:
962 [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 46.




963

964 1,8-(Ntrp)₂-**Pep-2**: 2366.08 (Molecular weight), 2367.79 (Found:[M+H]⁺), 1184.47
965 (Found: [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 47.



966
967


968 1,8-(Nse)₂-**Pep-2**: 2199.93 (Molecular weight), 2201.54 (Found:[M+H]⁺), 1099.63
969 [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 48.



970
971


972 1,8-(Ntyr)₂-**Pep-2**: 2319.99 (Molecular weight), 2321.48 (Found:[M+H]⁺), 1160.24
973 (Found:[M/2]⁺). UPLC-MS spectra were shown in Supplementary Fig. 49.

974




975
976

977 1-Nse-8-Ntyr-**Pep-2**: 2259.97 (Molecular weight), 2261.4 (Found:[M+H]⁺), 1131.59
978 (Found: [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 50.



979
980


981 13-Nte-Pep-2: 2168.84 (Molecular weight), 2169.66 (Found:[M+H]⁺), 1084.41 (Found:
982 [M/2]⁺). UPLC-MS spectra were shown in Supplementary Fig. 51.



983
984

985 13-Nhis-Pep-2: 2116.77 (Molecular weight), 2116.77 (Found:[M]⁺), 1058.75 (Found:
986 [M/2]⁺). UPLC-MS spectra were shown in Supplementary Fig. 52.


987



988
989


990 13-Ntyr-Pep-2: 2142.8 (Molecular weight), 2143.48 (Found:[M+H]⁺), 1072.25 (Found:
991 [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 53.

992




993
994

995 13-Nbce-Pep-2: 2288.94 (Molecular weight), 2289.23 (Found:[M]⁺), 1144.64 (Found:
996 [M/2]⁺). UPLC-MS spectra were shown in Supplementary Fig. 54.



997


998 1,14-(Nse)₂-**Pep-2**: 2199.93 (Molecular weight), 2201.01 (Found:[M+H]⁺), 1100.83
999 (Found: [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 55.



1000
1001


1002 Ncd-**Pep-2**: 3139.6 (Molecular weight), 1571.1 (Found: [M/2+H]⁺). UPLC-MS spectra
1003 were shown in Supplementary Fig. 56.

1004



1005
1006

1007 NHS-Rhodamine-labeled **Pep-3**: 2491.2 (Molecular weight), 2492.8 (Found:[M+H]⁺),
1008 1246.6 (Found: [M/2+H]⁺). UPLC-MS spectra were shown in Supplementary Fig. 57.



1009
1010

1011 Self-assembly of membrane-mimetic 2D nanomaterials from lipid-like peptoids

1012 Lyophilized and HPLC-grade peptoids were dissolved in the mixture of water and
1013 acetonitrile (v/v = 1:1) to make 5.0 mM clear solution, this clear solution was then
1014 transferred to 4 °C refrigerator for slow evaporation. Suspensions or gel-like materials
1015 containing a large amount of crystalline membranes were formed after a few days.

1016

1017 For testing the influence of ionic strength in peptoid membrane formation, lyophilized
1018 **Pep-3** powders were dissolved in the mixture of water and acetonitrile (v/v = 1:1) with
1019 presence of NaCl (0.5 M) to make 5.0 mM clear solution for slow crystallization at 4 °C.

1020

1021 For testing the change of solution pH in peptoid membrane formation, lyophilized
1022 peptoids were dissolved in the mixture of water and acetonitrile (v/v = 1:1) to make 5.0
1023 mM clear solution, then the above solution pH was adjusted by adding 2.0 M NaOH

1024 aqueous solution to a final pH value of 5.6, 7.4 or 10.50. This obtained clear solution was
1025 later used for slow evaporation in 4 °C refrigerator. Suspensions or gel-like materials
1026 containing a large amount of crystalline membranes were formed after a few days.

1027

1028 For self-assembly in the mixture of PBS and CH₃CN: Lyophilized peptoids were
1029 dissolved in the mixture of 1X PBS buffer and acetonitrile (v/v = 1:1) to make 5.0 mM
1030 clear solution, this clear solution was then transferred to 4 °C refrigerator for slow
1031 evaporation. Suspensions or gel-like materials containing a large amount of crystalline
1032 membranes were formed after a few days.

1033

1034 **Characterizations of peptoid membranes**

1035 Both *ex situ* (in air) and *in situ* (in fluid) AFM imaging were done in tapping mode or
1036 ScanAsyst mode at room temperature with a Bruker MultiMode 8. AFM samples were
1037 prepared by diluting peptoid membrane samples with water and using freshly cleaved
1038 mica as substrate. For stability test, pre-assembled Pep-3 membranes were incubated with
1039 water in AFM fluid cell, *in situ* AFM images at different time points were collected. Pep-
1040 3 stability in other solvents, such as pre-mixed water and acetonitrile (v/v = 1:1), ethanol,
1041 acetonitrile, aqueous solution with different salts and salt concentrations, was tested
1042 similarly by injected solvent into fluid cells or by fully exchanging these solvent with
1043 pre-injected waters in fluid cells. Similar protocols were used to prepare samples for salt-
1044 induced membrane thickness changes. For thermal stability test, gel-like materials of pre-
1045 assembled peptoid membranes in a 4.0 mL glass vial was placed in a 60 °C oven
1046 overnight, and then used to prepare *ex situ* AFM samples by diluting them with water on
1047 freshly-cleaved mica surface. For the *in situ* formation of single-layer Pep-3 membranes
1048 on mica surface: 2.0 mM aqueous solution of Pep-3 were prepared by mixing lyophilized
1049 3.0 μmol Pep-3 in 1.5 mL water, and 10 μL 2.0 M NaOH was added to assist peptoid
1050 dissolution; 25 μL the resulting 2.0 mM Pep-3 solution was diluted with 0.5 mL water
1051 and then well-mixed with 10 μL 0.1% TFA to get clear solution for *in situ* AFM studies.
1052 For Pep-3 membrane repair experiment, pre-assembled Pep-3 membranes were first
1053 deposited on mica surfaces and incubated with water. Selected membranes were
1054 purposely scratched to create defects using the AFM tip, and then aqueous solution of
1055 Pep-3 (10 μM, pH 4.3) was injected into fluid cell for *in situ* membrane repair. For
1056 patterning Ncd-Pep-2, an aqueous solution of Ncd-Pep-2 instead of Pep-3 was used for
1057 repair of defects-containing Pep-2 membranes.

1058

1059 TEM samples were prepared by pipetting one drop of water diluted peptoid membrane
1060 gels or suspensions onto carbon-coated electron microscopy grid; 2% phosphotungstic
1061 acid was then used for negative staining. TEM measurements were conducted on a 200-
1062 kV FEI Tecnai TEM microscope. SEM samples were prepared by pipetting one drop of
1063 water diluted peptoid membrane gels or suspensions onto silicon substrates. SEM
1064 measurements were performed on a FEI Helios Nanolab dual-beam focused ion
1065 beam/scanning electron microscopy (FIB/SEM) microscope. Powder X-ray diffraction
1066 data were collected at a multiple-wavelength anomalous diffraction and monochromatic
1067 macromolecular crystallography beamline, 8.3.1, at the Advanced Light Source located at
1068 Lawrence Berkeley National Laboratory. Beamline 8.3.1 has a 5 T single pole superbend

1069 source with an energy range of 5 - 17 keV. Data were collected with a 3×3 CCD array
1070 (ADSC Q315r) detector at a wavelength of 1.1159 Å. Datasets were collected with the
1071 detector 200 mm from the sample. Peptoid membrane suspensions or pellets were
1072 pipetted onto a Kapton mesh (MiTeGen) and dry. Data was processed with custom
1073 Python scripts.
1074

1075 **Molecular Dynamics Simulations**

1076 Since peptoid topologies and parameters are not present in standard MD forcefields, we
1077 generated them using the generalized amber forcefield (GAFF) and the Antechamber
1078 program.^{7,8} The AM1-BCC model^{9,10} was used to generate partial charges. GAFF
1079 parameters were converted into GROMACS-compatible topologies using the AcPype
1080 program,¹¹ and simulations were carried out using the AMBER03 forcefield¹² with the
1081 added peptoid parameters. GAFF-based peptoid models have been showed to correctly
1082 predict peptoid crystal structures.¹³ In addition, a recently developed CHARMM-based
1083 model accurately predicts the free energy barrier between the *cis* and *trans* isomers of the
1084 peptoid backbone amide bond.¹⁴

1085 Polymers were constructed in extended starting conformations with all-*trans* backbone
1086 amides using an in-house python script. While *cis* backbone amides are important in
1087 structures like the peptoid polyproline I helix¹⁵ and a cyclic peptoid nonamer,¹³ the *trans*
1088 configuration is preferred by about 3:1 for peptoids without branched sidechains.¹⁶ In
1089 addition, the barrier for *cis/trans* isomerization in peptoids is about $29*kT$,¹⁷ which is
1090 beyond the thermal motions that can be sampled on the simulation timescale.
1091 Furthermore, peptoid assembly into extended planar nanostructures like the peptoid
1092 nanosheet and membrane requires the linear, untwisted Σ -strand backbone
1093 conformation,¹⁸ which only forms with all-*trans* backbone amides.

1094 We start a variety of configurations with half the peptoids oriented up along the z-axis
1095 and half oriented down. The hydrophobic region (N_{4-Clpe} residues) is placed in the center
1096 to minimize exposed hydrophobic surface area. The sidechains are oriented along the y-
1097 axis, and the peptoids are stacked along the x-axis. Various system sizes were tried
1098 including 8 x 4, 16 x 4, and 16 x 6, and each system is solvated with a 2-nm layer of
1099 water in the z direction.

1100 After a steepest-descent minimization of the starting structure, the system was gradually
1101 heated from 0 to 300K in 50K increments, with 30 ps at each temperature followed by
1102 100 ps of relaxation at 300 K. MD simulations were performed with GROMACS 4.6.4
1103 ¹⁹. We used 1.0-nm cutoffs for van der Waals and Coulombic interactions and the
1104 particle-mesh Ewald method²⁰ for long-range electrostatic interactions. The simulations
1105 were performed in the NPT ensemble with a Parrinello-Rahman barostat²¹ with a 1 ps
1106 coupling time at 1 bar and anisotropic pressure coupling. A Nose-Hoover thermostat²² at
1107 300 K with 0.2 ps coupling time was applied separately to the polymer and to the solution
1108 (including ions). Simulations were performed for 500 to 1000 ns using a timestep of 2 fs.

1109 **X-ray diffraction calculations**

1110 We calculate X-ray (powder) diffraction from simulation structures according to the
1111 formula

1112 $I(\mathbf{q}) = \left| \sum_{j=1}^N f_j(q) \exp(i\mathbf{q} \cdot \mathbf{r}_j) \right|,$ (1)

1113 where the sum is over all atoms, $f_j(q)$ is the Cromer-Mann scattering factor for atom j at
 1114 magnitude q &, and \mathbf{r}_j are the coordinates of atom j . We choose $N_q = N_x * N_y * N_z$. $N_d =$
 1115 b_d/dr rounded to the nearest integer, where L_d is the length of the box vector in dimension
 1116 d , and dr is the (real space) grid spacing, which we set to 0.5 Å. For each triplet in i,j,k
 1117 space, the corresponding \mathbf{q} vector is $2\pi*(i/L_x, j/L_y, k/L_z)$. Since computed intensity scales
 1118 with the square of the system size, we normalize the computed intensity by the square of
 1119 the number of peptoid atoms.

1120 In addition, to facilitate identification of the most important peaks for comparison
 1121 between computation and experiment, we smoothed the computed XRD using a Gaussian
 1122 function. For each reflection in each structure, we distribute the intensity over q space
 1123 using a Gaussian

1124 $I(q) = \frac{I_0(q_0)}{\sigma\sqrt{2\pi}} \exp\left(-\frac{(q-q_0)^2}{2\sigma^2}\right),$ (2)

1125 where I_0 and q_0 are the intensity and q (magnitude) of the original reflection, respectively.
 1126 We choose σ so that 90% of the probability density falls within 0.025 Å⁻¹ of q_0 , which
 1127 leads to $\sigma = 0.0152$ Å⁻¹.

1128

1129 **Supplementary References**

1130

- 1131 1 Guo, W. H., Li, J. J., Wang, Y. A. & Peng, X. G. Luminescent CdSe/CdS
 1132 core/shell nanocrystals in dendron boxes: Superior chemical, photochemical and
 1133 thermal stability. *J. Am. Chem. Soc.* **125**, 3901-3909 (2003).
 1134 2 Sun, J., Stone, G. M., Balsara, N. P. & Zuckermann, R. N. Structure-conductivity
 1135 relationship for peptoid-based PEO-mimetic polymer electrolytes.
 1136 *Macromolecules* **45**, 5151-5156 (2012).
 1137 3 Petter, R. C., Salek, J. S., Sikorski, C. T., Kumaravel, G. & Lin, F. T. Cooperative
 1138 binding by aggregated mono-6-(alkylamino)-beta-cyclodextrins. *J. Am. Chem.*
 1139 *Soc.* **112**, 3860-3868 (1990).
 1140 4 Chen, C.-L., Qi, J., Tao, J., Zuckermann, R. N. & DeYoreo, J. J. Tuning calcite
 1141 morphology and growth acceleration by a rational design of highly stable protein-
 1142 mimetics. *Sci. Rep.* **4** (2014).
 1143 5 Zuckermann, R. N., Kerr, J. M., Kent, S. B. H. & Moos, W. H. Efficient method
 1144 for the preparation of peptoids oligo(N-substituted glycines) by submonomer
 1145 solid-phase synthesis. *J. Am. Chem. Soc.* **114**, 10646-10647 (1992).
 1146 6 Burkoth, T. S., Fafarman, A. T., Charych, D. H., Connolly, M. D. & Zuckermann,
 1147 R. N. Incorporation of unprotected heterocyclic side chains into peptoid oligomers
 1148 via solid-phase submonomer synthesis. *J. Am. Chem. Soc.* **125**, 8841-8845 (2003).
 1149 7 Wang, J., Wang, W., Kollman, P. A. & Case, D. A. Automatic atom type and
 1150 bond type perception in molecular mechanical calculations. *J. Mol. Graph.*
 1151 *Model.* **25**, 247-260 (2006).

1152 8 Wang, J. M., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A.
1153 Development and testing of a general amber force field. *J. Comput. Chem.* **25**,
1154 1157-1174 (2004).

1155 9 Jakalian, A., Bush, B. L., Jack, D. B. & Bayly, C. I. Fast, efficient generation of
1156 high-quality atomic Charges. AM1-BCC model: I. Method. *J. Comput. Chem.* **21**,
1157 132-146 (2000).

1158 10 Jakalian, A., Jack, D. B. & Bayly, C. I. Fast, efficient generation of high-quality
1159 atomic charges. AM1-BCC model: II. Parameterization and validation. *J. Comput.*
1160 *Chem.* **23**, 1623-1641 (2002).

1161 11 Sousa da Silva, A. & Vranken, W. ACPYPE - AnteChamber PYthon Parser
1162 interfacE. *BMC Res Notes* **5**, 1-8 (2012).

1163 12 Duan, Y. *et al.* A point-charge force field for molecular mechanics simulations of
1164 proteins based on condensed-phase quantum mechanical calculations. *J. Comput.*
1165 *Chem.* **24**, 1999-2012 (2003).

1166 13 Butterfoss, G. L. *et al.* De novo structure prediction and experimental
1167 characterization of folded peptoid oligomers. *Proc. Natl. Acad. Sci. U. S. A.* **109**,
1168 14320-14325 (2012).

1169 14 Mirijanian, D. T., Mannige, R. V., Zuckermann, R. N. & Whitelam, S.
1170 Development and use of an atomistic CHARMM-based forcefield for peptoid
1171 simulation. *J. Comput. Chem.* **35**, 360-370 (2014).

1172 15 Wu, C. W., Sanborn, T. J., Huang, K., Zuckermann, R. N. & Barron, A. E.
1173 Peptoid oligomers with α -chiral, aromatic side chains: Sequence requirements for
1174 the formation of stable peptoid helices. *J. Am. Chem. Soc.* **123**, 6778-6784 (2001).

1175 16 Sui, Q., Borchardt, D. & Rabenstein, D. L. Kinetics and equilibria of cis/trans
1176 isomerization of backbone amide bonds in peptoids. *J. Am. Chem. Soc.* **129**,
1177 12042-12048 (2007).

1178 17 Gasparro, F. P. & Kolodny, N. H. NMR determination of the rotational barrier in
1179 N,N-dimethylacetamide. A physical chemistry experiment. *J. Chem. Edu.* **54**, 258
1180 (1977).

1181 18 Mannige, R. V. *et al.* Peptoid nanosheets exhibit a new secondary-structure motif.
1182 *Nature* **526**, 415-420 (2015).

1183 19 Pronk, S. *et al.* GROMACS 4.5: a high-throughput and highly parallel open
1184 source molecular simulation toolkit. *Bioinformatics* **29**, 845-854 (2013).

1185 20 Darden, T., York, D. & Pedersen, L. Particle mesh ewald - an n.log(n) method for
1186 ewald sums in large systems. *J. Chem. Phys.* **98**, 10089-10092 (1993).

1187 21 Parrinello, M. & Rahman, A. polymorphic transitions in single-crystals - a new
1188 molecular-dynamics method. *J. Appl. Phys.* **52**, 7182-7190 (1981).

1189 22 Hoover, W. G. Canonical dynamics - equilibrium phase-space distributions. *Phys.*
1190 *Rev. A* **31**, 1695-1697 (1985).

1191